<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02315443</url>
  </required_header>
  <id_info>
    <org_study_id>NA-1-005</org_study_id>
    <secondary_id>171820</secondary_id>
    <nct_id>NCT02315443</nct_id>
  </id_info>
  <brief_title>Field Randomization of NA-1 Therapy in Early Responders</brief_title>
  <acronym>FRONTIER</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Intravenous NA-1 Initiated by Paramedics in the Field for Acute Cerebral Ischemia Within Three Hours of Symptom Onset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NoNO Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brain Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Djavad Mowafaghian Centre for Brain Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Stroke Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genome Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NoNO Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether NA-1 is effective in reducing global
      disability in patients with acute cerebral ischemia if administered early after symptom
      onset.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NA-1 is being developed as an emergency drug aimed at reducing global disability in patients
      with acute cerebral ischemia if administered early after symptom onset.

      The primary objective is to determine the efficacy of NA-1 in reducing global disability in
      patients with acute stroke. The secondary objectives are to determine the efficacy of NA-1 in
      reducing functional dependence, improving neurological outcome, improving activities of daily
      living, and increasing the proportion of subjects who are candidates for endovascular
      recanalization therapy.

      The leading safety objectives are to determine the effect of administering a target dose of
      2.60 mg/kg IV infusion of NA-1 within three hours of symptom onset by paramedics in the field
      on serious adverse events and 90-day mortality.

      This trial is a multicenter, randomized, double-blind, placebo-controlled, single dose study
      initiated prehospital in the ambulance. It is being conducted using Emergency Medical
      Services (EMS) in Canada. Subjects with suspected acute stroke will be identified in the
      field by trained paramedics using the approved stroke protocol in use by the local EMS
      system, and further screened for eligibility and approval by an on-call trial physician. The
      paramedics will administer the study drug. Upon arrival at the emergency department, subjects
      will receive standard-of-care.

      An Independent Data Monitoring Committee will perform safety reviews of the clinical data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2015</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Scale (mRS) scale</measure>
    <time_frame>90 days</time_frame>
    <description>The percentage of responders, using a sliding dichotomy on the mRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mRS shift analysis</measure>
    <time_frame>90 Days or the last rating</time_frame>
    <description>Shift to reduced functional dependence analyzed across the whole distribution of scores on the mRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with functional independence</measure>
    <time_frame>90 Days or the last rating</time_frame>
    <description>Proportion of subjects with functional independence, as defined by a score of a) 0-2 and b) 0-
1 on the mRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>90 Days or the last rating</time_frame>
    <description>Proportion of subjects with good neurological outcome, as defined by a score of 0-1 on the NIHSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>90 Days or the last rating</time_frame>
    <description>Proportion of subjects with functional independence in activities of daily living, as defined by a score of ≥ 95 on the Barthel Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eligibility for endovascular recanalization</measure>
    <time_frame>24 hours</time_frame>
    <description>Proportion of subjects who are deemed to be candidates for endovascular recanalization therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">558</enrollment>
  <condition>Acute Cerebral Ischemia</condition>
  <arm_group>
    <arm_group_label>NA-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.60 mg/kg of NA-1 administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NA-1</intervention_name>
    <arm_group_label>NA-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provisional diagnosis of acute stroke as identified by paramedics using the local
             stroke triage tool

          -  Respiratory rate 12-24 breaths per minute

          -  Oxygen saturation ≥ 90% on room air

          -  Systolic blood pressure &lt; 90 or &gt; 220 mmHg

          -  Weight 45-120 kg

          -  Last seen in usual state of health less than 3 hours before anticipated study drug
             initiation

          -  Independently ambulatory with or without devices prior to event

          -  LAMS score of 2-5 for at least 15 minutes and remains 2-5 at time of randomization

        Exclusion Criteria:

          -  Lack of IV access

          -  Canadian Triage and Acuity Scale Level 1 and/or uncorrected airway, breathing or
             significant circulatory problem

          -  Blood sugar &lt; 3 mmol/L (&lt; 55 mg/dL)

          -  Seizure at onset of symptoms or observed by paramedic

          -  Glasgow coma score of &lt;10

          -  Major head trauma in the last three months

          -  Recent stroke in the last three months with or without residual deficit

          -  Known or presumptive signs of pregnancy or breastfeeding

          -  Prisoner

          -  Long term care facility resident

          -  Known advance directive to not resuscitate

          -  Valid Emergency Health Services Do Not Resuscitate Consent Form

          -  Known participation in a clinical trial with an investigational drug or device within
             30 days preceding this trial

          -  Pre-existing neurologic, psychiatric, or advanced systemic condition that would
             preclude obtaining the neurological or functional outcome evaluations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Christenson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Swartz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Tymaisnki, M.D.</last_name>
    <phone>(416) 603-5899</phone>
    <email>mtymianski@nonoinc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathy Heard, M.Sc.</last_name>
    <phone>(416) 603-5899</phone>
    <email>kheard@nonoinc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kelowna General Hospital</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 1T2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksander Tkach, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Columbian Hospital</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 3W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Medvedev, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>British Columbia Ambulance Service and British Columbia Emergency Health Services</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5M 4X6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Dick, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital, Vancouver Coastal Health</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Benavente, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>December 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2014</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Prehospital</keyword>
  <keyword>NA-1</keyword>
  <keyword>Modified Rankin Scale</keyword>
  <keyword>Haemorrhagic stroke</keyword>
  <keyword>Transient ischemic attack</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

